NCT04450069 - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

May 6, 2024

Study Completion Date

May 6, 2024

Conditions

Relapsed/Refractory B-cell LymphomasDiffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Chronic Lymphocytic Leukemia (CLL)Marginal Zone Lymphoma (MZL)Mantle Cell LymphomaSmall Lymphocytic Lymphoma (SLL)Primary Mediastinal Large B Cell LymphomaTransformed Follicular LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic LymphomaBurkitt Lymphoma

Interventions

COMBINATION_PRODUCT

CLBR001 and SWI019

Investigational immunotherapy for B cell malignancies

Trial Locations (8)

10065

Weill Cornell Medical College - New York Presbyterian Hospital, New York

27157

Wake Forest Baptist Health, Winston-Salem

37203

Sarah Cannon Research Institute - Tennessee Oncology, Nashville

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

60637

University of Chicago, Chicago

78229

Sarah Cannon Research Institute - Texas Transplant Institute, San Antonio

91010

City of Hope National Medical Center, Duarte

92093

University of California at San Diego, San Diego

All Listed Sponsors

lead

Calibr, a division of Scripps Research

OTHER